ARA. Blythe Ryerson

A. Blythe Ryerson

*This is an algorithmically generated author record based on publicly available information.

A. Blythe Ryerson has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Assessment of Race, the 21-Gene Recurrence Score, and Breast Cancer Outcomes at Kaiser Permanente

    by Amanda F. Petrik, Charisma L. Jenkins, Ana G. Rosales, Terry Kimes, Ning Smith, Nathalie Johnson, Amy Morris, Suma Vupputuri, A. Blythe Ryerson, Matthew P. Banegas, et al.

    Background: It is well documented that Black and African American (AA) patients have the highest risk of recurrence of breast cancer. However, less is known about racial differences in gene expression profiling tests such as Oncotype DX that predicts cancer recurrence. This study aimed to assess the predictive differences in Oncotype DX scores for breast cancer outcomes between Black/AA and non-Hispanic White patients. Methods: We identified Oncotype DX testing status in patients ages 18–75 years who were newly diagnosed with breast cancer, assessed race and other factors among patients with different testing statuses, and described the distribution of the Oncotype DX score. Additionally, we assessed treatment, and multifactorial impact on outcomes by Oncotype DX score, including: receipt of chemotherapy, endocrine therapy, stage, and disease-related recurrence and mortality. Results: We identified 2577 eligible patients for the analysis. Black/AA patients had a 49% greater risk/hazard of mortality than non-Hispanic White (NHW) patients (multivariable model p-value 0.0444). Oncotype DX score differences were associated with mortality in the overall sample (multivariable model, p-value = 0.0281). Specifically, in the Oncotype DX-specific models, Black/AA patients with an Oncotype DX score of 0–16 had 73% greater risk of mortality than NHW patients (multivariable model p-value 0.0409). While all other Oncotype DX score categories showed elevated risks of mortality, they were not statistically significant. The Oncotype DX-specific multivariable models showed that, compared to NHW patients, recurrence was lower for Black/AA patients in the lower categories and higher in the upper categories, but results were not statistically significant. Conclusions: This study assessed recurrence and mortality outcomes by the recurrence score and found significantly higher rates of mortality among Black/AA patients in the lowest recurrence score category. Other studies have shown that recurrence scores add prognostic value during diagnosis. However, examining performance of these tools among diverse populations is imperative.

  • Statins and risk of cardiovascular disease: emulating a primary prevention trial in breast cancer survivors

    by Rienna G Russo, Miguel A Hernán, Issa J Dahabreh, Eric B Rimm, Lene H S Veiga, Amber N Hurson, Rochelle E Curtis, Ruth M Pfeiffer, Quiera S Booker, Macy E Corley, et al.

    Background: Limited evidence is available from randomized trials to guide clinical decision making for cardiovascular disease (CVD) prevention with statins among women with breast cancer. We leveraged real-world data to estimate the effect of statin therapy vs usual care on the 5-year risk of CVD among breast cancer survivors. Methods: We sequentially emulated target trials using the National Cancer Institute–Kaiser Permanente Breast Cancer Survivors Cohort. Women aged 40-84 years, diagnosed with stages 0-III breast cancer from 1993 to 2022, without CVD, no statins in the past 6 months, and low-density lipoprotein cholesterol from 100 to 160 mg/dL were included. The outcome was CVD (ischemic heart disease, stroke, and cardiomyopathy/heart failure). We compared statin therapy to usual care (no statins unless indicated) in intention-to-treat and per-protocol analyses. Results: Statin initiators were more likely to be older with a higher prevalence of cardiovascular comorbidities. In the intention-to-treat analysis, the 5-year risk difference was 0.3% (95% CI = −0.9 to 1.5), and risk ratio was 1.04 (95% CI = 0.86 to 1.25) for statin vs usual care. At 5 years, the proportion adherent to their initial strategy was 48% for statin and 24% for usual care. In the per-protocol analysis, the risk difference was −0.9% (95% CI = −2.9 to 2.2) and the risk ratio was 0.85 (95% CI = 0.51 to 1.36) for statin vs usual care. Conclusions: Our findings suggest that statin therapy may reduce the risk of CVD for breast cancer survivors, but the estimates are too imprecise for specific recommendations. Future research is needed to understand reasons for statin discontinuation, and opportunities to encourage adherence in this high-risk population.

  • Open Access

    Severe Outcomes, Readmission, and Length of Stay Among COVID-19 Patients with Intellectual and Developmental Disabilities

    by Alain K. Koyama, Emilia H. Koumans, Kanta Sircar, Amy Lavery, Joy Hsu, A. Blythe Ryerson, David A. Siegel


  • Open Access

    Surveillance for Cancer Incidence and Mortality — United States, 2012

    by Simple D. Singh, S. Jane Henley, A. Blythe Ryerson

    This report provides, in tabular and graphic form, official federal statistics on the occurrence of cancer for 2012 and trends for 1999-2012 as reported by CDC and the National Cancer Institute (NCI) (1). Cancer incidence data are from population-based cancer registries that participate in CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results (SEER) program reported as of November 2014. Cancer mortality data are from death certificate information reported to state vital statistics offices through 2012 and compiled into a national file for the entire United States by CDC's National Center for Health Statistics' (NCHS) National Vital Statistics System (NVSS). This report is a part of the Summary of Notifiable Noninfectious Conditions and Disease Outbreaks - United States, which encompasses various surveillance years but is being published in 2016 (2). The Summary of Notifiable Noninfectious Conditions and Disease Outbreaks appears in the same volume of MMWR as the annual Summary of Notifiable Infectious Diseases (3).